Related Experiment Videos
Targeting angiogenesis in lung cancer
1Department of Medical Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232-6307, USA. alam.sandler@vanderbilt.edu
Seminars in Oncology
|February 7, 2006
Summary
New antiangiogenic therapies targeting angiogenesis show promise for improving survival in non-small cell lung cancer patients. These targeted treatments represent a significant advancement in cancer therapy, offering new hope for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Lung cancer prognosis remains poor despite advancements in chemotherapy.
- Novel therapeutic targets are emerging from signal transduction pathways crucial for tumor growth.
- Angiogenesis, a key process in tumor development, is a focus for targeted therapies.
Purpose of the Study:
- To review antiangiogenic therapeutic monoclonal antibodies for non-small cell lung cancer (NSCLC).
- To discuss the potential of targeting angiogenesis in NSCLC treatment.
Main Methods:
- Review of recent studies on antiangiogenic therapies.
- Focus on monoclonal antibodies targeting angiogenesis.
- Discussion of combination therapies with standard chemotherapy.
Main Results:
- Antiangiogenic therapies show promise as single agents and in combination with chemotherapy.
- Targeted therapeutics demonstrate efficacy in recent studies.
- Monoclonal antibodies targeting angiogenesis are a validated treatment modality.
Conclusions:
- Antiangiogenic monoclonal antibodies are a promising new treatment for NSCLC.
- Targeting angiogenesis offers a novel approach to improve survival in lung cancer patients.
- Further development of these targeted therapies is warranted.